PUK9 INTERSTITIAL CYSTITIS COSTS, TREATMENT AND COMORBIDITIES IN AN EMPLOYED POPULATION  by Wu, EQ et al.
415Abstracts
controlled trials; and 3) previous pharmacoeconomic OAB
studies. Due to lack of variance for success rate in published
reports, sensitivity analyses used +/- 50%. RESULTS: Success
rates for the treatments were 35.6%(OxyIR), 23.0%(OxyER),
39.0%(OxyTD), 24.6%(TolIR), and 16.8%(TolER). Cost per
complete continence was lowest for OxyIR ($5777), followed by
OxyTD ($6189), TolIR ($8658), OxyER ($9121), and TolER
($11,850). OxyER, TolIR, and TolER were dominated by OxyIR
and OxyTD. Comparing OxyIR, use of OxyTD was an addi-
tional $9916 per person with complete continence. Sensitivity
analyses found that success rate was the key parameter driving
the analysis. When the success rate of OxyIR varied from 17.8%
to 53.4%, the ICER of OxyTD changed from $1462 to being
dominated. When the success rate of OxyTD varied from 19.5%
to 58.5%, the ICER of OxyTD changed from being dominated
to $1151. Sensitivity analyses of other model parameters were
found to not change the rank orders of treatments. CONCLU-
SION: The results of this study suggested OxyIR is the most 
cost-effective treatment for overactive bladder among various
preparations of oxybutynin and tolterodine. The second cost-
effective agent is OxyTD.
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OBJECTIVE: To evaluate the economic value of a pharmaceu-
tical product, Kremezin, in treating patients with chronic renal
failure (CRF) by estimating the amount of cost savings due to its
effect of delaying the onset of receiving dialysis treatments.
METHODS: The types of costs included were direct medical and
non-medical costs, and productivity loss costs. The information
about the effect of Kremezin was obtained from the results of
randomized controlled clinical trials. Cost information was
derived from administrative data for 20 hemodialysis and 20
peritoneal patients from one tertiary care hospital, and 20
hemodialysis patients from one free-standing dialysis center. Per-
capita cost savings resulting from Kremezin therapy were sepa-
rately estimated for the cases delaying the onset of hemodialysis
and the cases for peritoneal dialysis. By computing the weighted
average for the cases of hemodialysis and peritoneal dialsyis, the
expected per-capita cost savings of a patient with CRF was
obtained. Using the discount rate of 5%, future cost savings were
converted to the present value. Budget impact analysis was 
performed to estimate the expected national cost savings if 
Kremezin is administered to 25%, 50%, and 75% of the total
incident dialysis patients in 2004. RESULTS: Depending on the
effect of Kremezin in delaying the onset of dialysis treatments by
one, two, or four years, a patient with CRF could save costs by
1.8¢ 5.5, 1.6¢ 5.1 and 3.4¢ 10.6 million Korean Won (KW),
respectively from the perspectives of insurer, patient, and society.
Also, the national ﬁnancial impact of adopting Kremezin for
25%, 50%, and 75% of the total incident dialysis patients was
estimated as cost savings of about 61,511¢ 579,162 million KW
per year in Korea. CONCLUSION: The estimated amount of
cost savings resulting from treating CRF patients with Kremezin
conﬁrms that its effect of delaying the onset of dialysis treatments
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OBJECTIVE: To describe treatment utilization and associated
costs for women diagnosed with stress urinary incontinence in a
Medicaid population. METHODS: We utilized a pooled data-
base consisting of health care claims for women enrolled in 
Medicaid in one of four states. After identifying women with a
coded diagnosis consistent with stress urinary incontinence
(SUI), treatment utilization and costs were determined for the 12
months after the urinary incontinence diagnosis. RESULTS: Of
the 13,672 women with a diagnosis of SUI, average urinary
incontinence-related costs were approximately $800 in the 12-
month study period, accounting for less than 0.1% of total Med-
icaid spending. Approximately one-third of the SUI patients
received an anticholinergic medication in the study period,
though these medications are not indicated for SUI treatment. A
total of 13% of women underwent a surgery for SUI in the study
period, with sling procedures performed most commonly. Mean
UI-speciﬁc costs in the study period for the surgical and non-
surgical SUI patients were $3258 and $424 (p < 0.001) respec-
tively. CONCLUSIONS: While overall population estimates of
the prevalence of any stress urinary incontinence symptoms often
are high, diagnosis and treatment utilization in the Medicaid
population is low, and overall costs of SUI treatment in Medic-
aid currently are minimal. Further efforts to understand the
appropriate detection, diagnosis, and treatment of women with
SUI are needed.
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OBJECTIVES: This study assessed per patient direct medical
costs and indirect work loss of diagnosed interstitial cystitis
(“IC”) patients from an employer’s perspective. Treatment
pattern of IC was also assessed. METHODS: Patients under age
65 with at least one IC diagnosis (n = 749) were drawn from a
de-identiﬁed, administrative database of approximately two-
million beneﬁciaries that includes medical, drug, and disability
claims for 1999–2002. A 2 :1 matched non-IC control sample
was randomly selected based on matching demographic charac-
teristics (i.e. age, gender, region of residence). Annual costs and
comorbidities were compared between IC and the non-IC
samples descriptively. A multivariate two-part regression model
was applied to estimate IC excess medical costs and indirect
work loss costs while adjusting for observed patient demo-
graphics and comorbidities. All costs were adjusted to 2002 USD
using Consumer Price Index (“CPI”). Intent-to-treat approach
was adopted to proﬁle treatment patterns of IC. RESULTS: An
average IC patient had 130% higher direct medical costs ($3756)
and 80% higher indirect costs ($725) than a non-IC patient.
Compared with non-IC patients, IC patients had higher diag-
nostic prevalence of prostatitis (Relative Risk (“RR”) = 40.0, P
< 0.05), endometriosis (RR = 7.4, P < 0.05), vulvodynia (RR =
6.9, P < 0.05), chronic pelvic pain (RR = 5.8, P < 0.05), and
urinary tract infections (RR = 5.1, P < 0.05). IC patients were
also more likely to suffer from depression (RR = 2.8, P < 0.05)
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and anxiety (RR = 4.4, P < 0.05). Seventeen percent of 
IC patients received pentosan polysulfate sodium, the only
approved oral drug indicated for IC, within the ﬁrst two months
following the initial diagnosis. Approximately half of IC patients
received no drug treatment within two months following the
diagnosis. CONCLUSIONS: IC is a costly disease associated
with increased risk of comorbidities. IC patients are commonly
untreated.
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OBJECTIVES: To evaluate evolving epoetin alfa (EPO) and 
darbepoetin alfa (DARB) dosing patterns from 2002–2004 in
patients with pre-dialysis chronic kidney disease (CKD) receiv-
ing care in nephrology clinics. METHODS: A random panel of
approximately 250 nephrologists was requested bimonthly to
review the medical records of their last two anemic pre-dialysis
CKD patients seen currently receiving an erythropoiesis-
stimulating therapy (EST). Data on patient demographics, co-
morbid conditions, CKD status, EST dose, and frequency of
administration were collected every two months to evaluate
changes over time. RESULTS: A yotal of 1585 patient charts
were reviewed from November, 2002 to May, 2004 (EPO: 1047;
DARB: 538). Patient demographics, comorbid conditions, base-
line hemoglobin, and renal function were similar between
groups. Weekly and extended (>Q2W) dosing patterns were seen
in both groups (May, 2004—EPO: QW, 62%; Q2W, 24%;
Other, 14%; DARB: QW, 32%; Q2W, 51%; Other, 19%). A
decrease in the dose only ratio (units EPO: mcg DARB) from 
276 :1 in November, 2002 (average weekly dose—EPO: 10,481
units; DARB: 38mcg) to 217 :1 (average weighted weekly dose—
EPO: 9981 units; DARB: 46mcg) in May, 2004 was observed.
The average weekly dose over the course of the study (EPO:
10,172 units; DARB: 41mcg) corresponded to weekly costs of
$113 and $164 for EPO and DARB (based on 2003 wholesale
acquisition cost), respectively. CONCLUSIONS: Increasing
DARB doses have been seen from November, 2002 through May,
2004, resulting in a lower dose only conversion ratio and greater
average weekly drug costs compared to EPO. These analyses will
assist clinicians and formulary decision makers in identifying
real-world equivalent dosing and subsequent cost of treatment
of these agents.
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OBJECTIVE: To examine levels of persistence and compliance
with long-acting tolterodine (TOL) versus immediate- or
extended-release oxybutynin (OXY-I or OXY-X) among com-
mercially-insured patients with overactive bladder (OAB).
METHODS: Data were obtained from the PharMetrics Patient-
Centric Database on patients diagnosed with OAB who started
therapy with TOL, OXY-I, or OXY-X between January 2001
and December 2002. Medication adherence was tracked for 12
months. Persistence with medication was calculated based on the
time from the index prescription to ﬁrst discontinuation. Dis-
continuation was deﬁned as a gap in therapy exceeding 2 times
the therapy-days supplied on the previous prescription. Compli-
ance was assessed as the ratio of the total number of days sup-
plied to the number of days persistent with medication. Results
were compared between groups descriptively. Chi-square tests
were performed comparing the proportions persistent at 1, 2, 3,
and 12 months. RESULTS: A total of 15,394 TOL, 7934 OXY-
X, and 7963 OXY-I patients were available for analysis. Com-
pliance did not differ between TOL (77.4%) and OXY-X
(74.3%), but was substantially lower for OXY-I patients
(60.9%). The mean (±SD) number of days on therapy was higher
among TOL (139 ± 132) than OXY-X (115 ± 122) or OXY-I
(60 ± 85) patients. Persistence dropped more sharply over time
among OXY-I and OXY-X than among TOL patients. At 1
month, 94.1% of TOL patients were persistent, declining to
45.9% at 3 months, and 19.9% at 12 months. Among OXY-X
patients, 89.0%, 38.2%, and 13.9% were persistent after 1, 3,
and 12 months, respectively. Corresponding ﬁgures for OXY-I
patients were 65.6%, 16.6%, and 4.3%. Between-group differ-
ences (ie, OXY-X and OXY-I vs TOL respectively) were statis-
tically signiﬁcant (p values <0.0001) at each time point.
CONCLUSIONS: Although compliance was comparable among
TOL and OXY-I patients, TOL was associated with longer dura-
tion of use relative to OXY-X and OXY-I.
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OBJECTIVE: To evaluate adherence with medications used to
treat overactive bladder (OAB) in a managed care population.
METHODS: This was retrospective study performed using pre-
scription drug claims data from a managed care organization for
medications used in the treatment of OAB. The data set analyzed
contained 18-months of prescriptions claims but only members
that were newly started on an OAB medication between study
months six and 12 were included in our analysis. The adherence
indicators used in this study were the medication possession ratio
for the ﬁrst 180 days of therapy (MPR 180) and persistence on
therapy at six months. The factors inﬂuencing the MPR 180 and
persistence were evaluated using multi-factorial linear regression,
and binary logistic regression, respectively. Factors evaluated
were age, gender, type of insurance plan, and the speciﬁc OAB
medication. RESULTS: There were 489 members initiated on
OAB medications during the study period. Immediate release
oxybutynin accounted for 81.6% of OAB medications initiated.
For all OAB medications, the MPR 180 was 37.4% and persis-
tence at six-months was 31.5%. Speciﬁc OAB medication was
the only factor that was signiﬁcantly correlated with both the
MPR 180 (P < 0.001) and persistence on medications (P =
0.013). Patients initiated on extended-release oxybutynin and
extended-release tolterodine exhibited a signiﬁcantly higher
MPR 180 and were more persistent compared to patients initi-
ated on immediate-release oxybutynin. CONCLUSIONS:
Adherence to medications used to treat OAB tends to be poor.
Adherence with extended release formulations was signiﬁcantly
better than the most commonly used immediate-release generic
preparation. Poor adherence to OAB medication may hinder
members from achieving optimal therapeutic outcomes.
